Bracco Diagnostics Inc. Creates First and Only U.S. FDA-Approved Multi-Dose Compliant Contrast Medium as Breakthrough Solution for Point-of-Care Use in the CT Suite
Bracco Diagnostic Inc. (BDI) today announced the availability of its innovative ISOVUE® (iopamidol injection) Imaging Bulk Package.Press release
Bracco Diagnostics Inc. receives U.S. FDA Approval for new Ultrasound Contrast Agent
Lumason™ (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, now available for use in adults with suboptimal echocardiograms.Press release
Click here to learn about the TRUTH1 Study.
Reference 1. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Zižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2014 Oct 9. [Epub ahead of print]